Clinical trial
MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed…
NCT00059995 · Memorial Sloan Kettering Cancer Center, Other · Completed
Key facts
| NCT number | NCT00059995 |
|---|---|
| Title | MDX-060 Monoclonal Antibody in Treating Patients With Refractory or Relapsed Lymphoma |
| Official title | Phase I/II Open Label, Dose-Escalating Study of MDX-060 Administered Weekly for 4 Weeks in Patients With Refractory/Relapsed CD30 Lymphoma |
| Lead sponsor | Memorial Sloan Kettering Cancer Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Biological |
| Interventions | iratumumab |
| Start date | Jan 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Nov 1, 2009 |
| First posted | May 7, 2003 |
| Last update posted | May 30, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: